{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:49:32Z","timestamp":1768013372873,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.110211","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T06:08:14Z","timestamp":1598422094000},"page":"110211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis"],"prefix":"10.1016","volume":"144","author":[{"given":"Wei","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110211_b0005","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110211_b0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110211_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.mehy.2020.110211_b0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.mehy.2020.110211_b0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mehy.2020.110211_b0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2017.88","article-title":"Gut microbiota and IBD: causation or correlation?","volume":"14","author":"Ni","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.mehy.2020.110211_b0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3389\/fimmu.2017.00942","article-title":"Interactions between intestinal microbiota and host immune response in inflammatory bowel disease","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.mehy.2020.110211_b0040","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3748\/wjg.v22.i3.1078","article-title":"Role of antibiotics for treatment of inflammatory bowel disease","volume":"22","author":"Nitzan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110211_b0045","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.crohns.2014.05.010","article-title":"Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report","volume":"8","author":"Turner","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.mehy.2020.110211_b0050","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1097\/MPG.0000000000002034","article-title":"Combination antibiotics improves disease activity and alters microbial communities in children with ulcerative colitis","volume":"67","author":"Kordy","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.mehy.2020.110211_b0055","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/ajg.2010.84","article-title":"Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial","volume":"105","author":"Ohkusa","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110211_b0060","first-page":"9","article-title":"Intestinal bacteria and ulcerative colitis","volume":"4","author":"Cummings","year":"2003","journal-title":"Curr Issues Intest Microbiol"},{"key":"10.1016\/j.mehy.2020.110211_b0065","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ibd\/izy067","article-title":"Antibiotics in IBD: still a role in the biological era?","volume":"24","author":"Ledder","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.mehy.2020.110211_b0070","doi-asserted-by":"crossref","first-page":"814","DOI":"10.14309\/ajg.0000000000000604","article-title":"Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework","volume":"115","author":"Shah","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110211_b0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.mehy.2020.110211_b0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","article-title":"Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic","volume":"47","author":"Davies","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.mehy.2020.110211_b0085","first-page":"580","article-title":"Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease","volume":"27","author":"Cox","year":"1998","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.mehy.2020.110211_b0090","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.14540","article-title":"Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis","volume":"47","author":"Damman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mehy.2020.110211_b0095","first-page":"124","article-title":"Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence","volume":"32","author":"Mertz","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110211_b0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00054725-199712000-00007","article-title":"Interactions between chronic liver disease and inflammatory bowel disease","volume":"3","author":"Loftus","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.mehy.2020.110211_b0105","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110211_b0110","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.mehy.2020.110211_b0115","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","article-title":"The treatment-naive microbiome in new-onset Crohn's disease","volume":"15","author":"Gevers","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.mehy.2020.110211_b0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","article-title":"Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci","volume":"57","author":"Folseraas","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.mehy.2020.110211_b0125","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.1233521","article-title":"Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity","volume":"339","author":"Markle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.mehy.2020.110211_b0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/mi.2014.53","article-title":"Commensal Gram-positive bacteria initiates colitis by inducing monocyte\/macrophage mobilization","volume":"8","author":"Nakanishi","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.mehy.2020.110211_b0135","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/MEG.0000000000001223","article-title":"Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis","volume":"30","author":"de Chambrun","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.mehy.2020.110211_b0140","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis","volume":"68","author":"Tan","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.mehy.2020.110211_b0145","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/gut.26.12.1380","article-title":"Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis","volume":"26","author":"Dickinson","year":"1985","journal-title":"Gut"},{"key":"10.1016\/j.mehy.2020.110211_b0150","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000475660","article-title":"Oral vancomycin and gentamicin for treatment of very early onset inflammatory bowel disease","volume":"95","author":"Lev-Tzion","year":"2017","journal-title":"Digestion"},{"key":"10.1016\/j.mehy.2020.110211_b0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.mehy.2020.110211_b0160","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/MCG.0000000000000024","article-title":"Ciprofloxacin usage and bacterial resistance patterns in Crohn's disease patients with abscesses","volume":"48","author":"Park","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110211_b0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4254\/wjh.v11.i1.19","article-title":"Treatment of primary sclerosing cholangitis in children","volume":"11","author":"Laborda","year":"2019","journal-title":"World J Hepatol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720321435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720321435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:33:18Z","timestamp":1759692798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720321435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":33,"alternative-id":["S0306987720321435"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110211","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110211"}}